share_log

EXCLUSIVE: SAB Biotherapeutics Tells Benzinga SAB Highlights Data On SAB-176 For Seasonal And Pandemic Influenza And SAB-185 For COVID-19, Showing Broad Efficacy Against Highly Mutating Viruses Associated With Respiratory Disease

Benzinga Real-time News ·  Nov 3, 2022 08:41
EXCLUSIVE: SAB Biotherapeutics Tells Benzinga SAB Highlights Data On SAB-176 For Seasonal And Pandemic Influenza And SAB-185 For COVID-19, Showing Broad Efficacy Against Highly Mutating Viruses Associated With Respiratory Disease
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment